683 related articles for article (PubMed ID: 25467702)
1. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
[TBL] [Abstract][Full Text] [Related]
4. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
Miller OH; Moran JT; Hall BJ
Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
[TBL] [Abstract][Full Text] [Related]
5. The role of glutamate on the action of antidepressants.
Hashimoto K
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
[TBL] [Abstract][Full Text] [Related]
6. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Owen RT
Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
[TBL] [Abstract][Full Text] [Related]
7. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
[TBL] [Abstract][Full Text] [Related]
8. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
9. Ketamine: The final frontier or another depressing end?
Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
[TBL] [Abstract][Full Text] [Related]
10. Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.
Ren Z; Pribiag H; Jefferson SJ; Shorey M; Fuchs T; Stellwagen D; Luscher B
Biol Psychiatry; 2016 Sep; 80(6):457-468. PubMed ID: 27062563
[TBL] [Abstract][Full Text] [Related]
11. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
Maeng S; Zarate CA
Curr Psychiatry Rep; 2007 Dec; 9(6):467-74. PubMed ID: 18221626
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant effects of ketamine in depressed patients.
Berman RM; Cappiello A; Anand A; Oren DA; Heninger GR; Charney DS; Krystal JH
Biol Psychiatry; 2000 Feb; 47(4):351-4. PubMed ID: 10686270
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.
Aleksandrova LR; Phillips AG; Wang YT
J Psychiatry Neurosci; 2017 Jun; 42(4):222-229. PubMed ID: 28234212
[TBL] [Abstract][Full Text] [Related]
15. Ketamine and the next generation of antidepressants with a rapid onset of action.
Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
[TBL] [Abstract][Full Text] [Related]
16. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
17. New targets for rapid antidepressant action.
Machado-Vieira R; Henter ID; Zarate CA
Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
[TBL] [Abstract][Full Text] [Related]
18. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
19. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID; Park LT; Zarate CA
CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
[TBL] [Abstract][Full Text] [Related]
20. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
